Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Dare Bioscience (DARE) EBIAT (2016 - 2025)

Dare Bioscience's EBIAT history spans 11 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, EBIAT rose 74.58% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$13.4 million, down 229.52%, while the annual FY2025 figure was -$13.4 million, 230.57% down from the prior year.
  • EBIAT reached -$1.4 million in Q4 2025 per DARE's latest filing, up from -$3.6 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $12.9 million in Q2 2024 to a low of -$15.9 million in Q4 2022.
  • Average EBIAT over 5 years is -$5.9 million, with a median of -$6.9 million recorded in 2022.
  • Peak YoY movement for EBIAT: crashed 2216.49% in 2023, then soared 247.34% in 2024.
  • A 5-year view of EBIAT shows it stood at -$9.5 million in 2021, then tumbled by 67.08% to -$15.9 million in 2022, then surged by 68.28% to -$5.1 million in 2023, then dropped by 8.87% to -$5.5 million in 2024, then skyrocketed by 74.58% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's EBIAT are -$1.4 million (Q4 2025), -$3.6 million (Q3 2025), and -$4.0 million (Q2 2025).